Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved

Wiehe, Kevin; Easterhoff, David; Luo, Kan; Nicely, Nathan I.; Bradley, Todd; Jaeger, Frederick H.; Dennison, S. Moses; Zhang, Ruijun; Lloyd, Krissey E.; Stolarchuk, Christina; Parks, Robert; Sutherland, Laura L.; Scearce, Richard M.; Morris, Lynn; Kaewkungwal, Jaranit; Nitayaphan, Sorachai; Pitisuttithum, Punnee; Rerks-Ngarm, Supachai; Sinangil, Faruk; Phogat, Sanjay; Michael, Nelson L.; Kim, Jerome H.; Kelsoe, Garnett; Montefiori, David C.; Tomaras, Georgia D.; Bonsignori, Mattia; Santra, Sampa; Kepler, Thomas B.; Alam, S. Munir; Moody, M. Anthony; Liao, Hua-Xin; Haynes, Barton F.

doi:10.1016/j.immuni.2014.11.014

Title: Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved

Full Record
Other Related Research

Abstract

In HIV-1, the ability to mount antibody responses to conserved, neutralizing epitopes is critical for protection. Here we have studied the light chain usage of human and rhesus macaque antibodies targeted to a dominant region of the HIV-1 envelope second variable (V2) region involving lysine (K) 169, the site of immune pressure in the RV144 vaccine efficacy trial. We found that humans and rhesus macaques used orthologous lambda variable gene segments encoding a glutamic acid-aspartic acid (ED) motif for K169 recognition. Structure determination of an unmutated ancestor antibody demonstrated that the V2 binding site was preconfigured for ED motif-mediated recognition prior to maturation. Thus, light chain usage for recognition of the site of immune pressure in the RV144 trial is highly conserved across species. In conclusion, these data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode.

Publication Date:: Mon Dec 01 00:00:00 EST 2014

Research Org.:: Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: USDOE Office of Science (SC), Basic Energy Sciences (BES); Bill & Melinda Gates Foundation; National Institutes of Health (NIH)

OSTI Identifier:: 1233905

Alternate Identifier(s):: OSTI ID: 1227575; OSTI ID: 1258693

Grant/Contract Number:: W-31-109-Eng-38; P30-AI-64518; 5T32-AI007392; OPP1033098; UMI-AI100645

Resource Type:: Published Article

Journal Name:: Immunity

Additional Journal Information:: Journal Name: Immunity Journal Volume: 41 Journal Issue: 6; Journal ID: ISSN 1074-7613

Publisher:: Elsevier

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES

Citation Formats


                    Wiehe, Kevin, Easterhoff, David, Luo, Kan, Nicely, Nathan I., Bradley, Todd, Jaeger, Frederick H., Dennison, S. Moses, Zhang, Ruijun, Lloyd, Krissey E., Stolarchuk, Christina, Parks, Robert, Sutherland, Laura L., Scearce, Richard M., Morris, Lynn, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Sinangil, Faruk, Phogat, Sanjay, Michael, Nelson L., Kim, Jerome H., Kelsoe, Garnett, Montefiori, David C., Tomaras, Georgia D., Bonsignori, Mattia, Santra, Sampa, Kepler, Thomas B., Alam, S. Munir, Moody, M. Anthony, Liao, Hua-Xin, and Haynes, Barton F. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved.  United States: N. p., 2014. 
Web.  doi:10.1016/j.immuni.2014.11.014.

Copy to clipboard


                    Wiehe, Kevin, Easterhoff, David, Luo, Kan, Nicely, Nathan I., Bradley, Todd, Jaeger, Frederick H., Dennison, S. Moses, Zhang, Ruijun, Lloyd, Krissey E., Stolarchuk, Christina, Parks, Robert, Sutherland, Laura L., Scearce, Richard M., Morris, Lynn, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Sinangil, Faruk, Phogat, Sanjay, Michael, Nelson L., Kim, Jerome H., Kelsoe, Garnett, Montefiori, David C., Tomaras, Georgia D., Bonsignori, Mattia, Santra, Sampa, Kepler, Thomas B., Alam, S. Munir, Moody, M. Anthony, Liao, Hua-Xin, & Haynes, Barton F. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved.  United States.  https://doi.org/10.1016/j.immuni.2014.11.014

Copy to clipboard


                    Wiehe, Kevin, Easterhoff, David, Luo, Kan, Nicely, Nathan I., Bradley, Todd, Jaeger, Frederick H., Dennison, S. Moses, Zhang, Ruijun, Lloyd, Krissey E., Stolarchuk, Christina, Parks, Robert, Sutherland, Laura L., Scearce, Richard M., Morris, Lynn, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Sinangil, Faruk, Phogat, Sanjay, Michael, Nelson L., Kim, Jerome H., Kelsoe, Garnett, Montefiori, David C., Tomaras, Georgia D., Bonsignori, Mattia, Santra, Sampa, Kepler, Thomas B., Alam, S. Munir, Moody, M. Anthony, Liao, Hua-Xin, and Haynes, Barton F. Mon .  
"Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved".  United States.  https://doi.org/10.1016/j.immuni.2014.11.014.

Copy to clipboard


                    
@article{osti_1233905,

  title        = {Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved},

  author       = {Wiehe, Kevin and Easterhoff, David and Luo, Kan and Nicely, Nathan I. and Bradley, Todd and Jaeger, Frederick H. and Dennison, S. Moses and Zhang, Ruijun and Lloyd, Krissey E. and Stolarchuk, Christina and Parks, Robert and Sutherland, Laura L. and Scearce, Richard M. and Morris, Lynn and Kaewkungwal, Jaranit and Nitayaphan, Sorachai and Pitisuttithum, Punnee and Rerks-Ngarm, Supachai and Sinangil, Faruk and Phogat, Sanjay and Michael, Nelson L. and Kim, Jerome H. and Kelsoe, Garnett and Montefiori, David C. and Tomaras, Georgia D. and Bonsignori, Mattia and Santra, Sampa and Kepler, Thomas B. and Alam, S. Munir and Moody, M. Anthony and Liao, Hua-Xin and Haynes, Barton F.},

  abstractNote = {In HIV-1, the ability to mount antibody responses to conserved, neutralizing epitopes is critical for protection. Here we have studied the light chain usage of human and rhesus macaque antibodies targeted to a dominant region of the HIV-1 envelope second variable (V2) region involving lysine (K) 169, the site of immune pressure in the RV144 vaccine efficacy trial. We found that humans and rhesus macaques used orthologous lambda variable gene segments encoding a glutamic acid-aspartic acid (ED) motif for K169 recognition. Structure determination of an unmutated ancestor antibody demonstrated that the V2 binding site was preconfigured for ED motif-mediated recognition prior to maturation. Thus, light chain usage for recognition of the site of immune pressure in the RV144 trial is highly conserved across species. In conclusion, these data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode.},

  doi          = {10.1016/j.immuni.2014.11.014},

  journal      = {Immunity},

  number       = 6,

  volume       = 41,

  place        = {United States},

  year         = {Mon Dec 01 00:00:00 EST 2014},

  month        = {Mon Dec 01 00:00:00 EST 2014}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1016/j.immuni.2014.11.014

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 49 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

Journal Article Nicely, Nathan I. ; Wiehe, Kevin ; Kepler, Thomas B. ; ... - EBioMedicine

Human monoclonal antibody CH58 isolated from an RV144 vaccinee binds at Lys169 of the HIV-1 Env gp120 V2 region, a site of vaccine-induced immune pressure. CH58 neutralizes HIV-1 CRF_01 AE strain 92TH023 and mediates ADCC against CD4 + T cell targets infected with CRF_01 AE tier 2 virus. CH58 and other antibodies that bind to a gp120 V2 epitope have a second light chain complementarity determining region (LCDR2) bearing a glutamic acid, aspartic acid (ED) motif involved in forming salt bridges with polar, basic side amino acid side chains in V2. In an effort to learn how V2 responses develop,more »« less
Cited by 13
https://doi.org/10.1016/j.ebiom.2015.06.016
Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice

Journal Article Wiehe, Kevin ; Nicely, Nathan I. ; Lockwood, Bradley ; ... - Journal of Immunology

In the RV144 gp120 HIV vaccine trial, decreased transmission risk was correlated with Abs that reacted with a linear epitope at a lysine residue at position 169 (K169) in the HIV-1 envelope (Env) V2 region. The K169 V2 response was restricted to Abs bearing Vλ rearrangements that expressed aspartic acid/glutamic acid in CDR L2. The AE.A244 gp120 in AIDSVAX B/E also bound to the unmutated ancestor of a V2-glycan broadly neutralizing Ab, but this Ab type was not induced in the RV144 trial. In this study, we sought to determine whether immunodominance of the V2 linear epitope could be overcomemore »« less
Cited by 6
https://doi.org/10.4049/jimmunol.1601640

Full Text Available
Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

Journal Article Easterhoff, David ; Moody, M. Anthony ; Fera, Daniela ; ... - PLoS Pathogens

The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (bnAbs), no plasma bnAb activity was induced. The RV305 (NCT01435135) HIV-1 clinical trial was a placebo-controlled randomized double-blinded study that assessed the safety and efficacy of vaccine boosting on B cell repertoires. HIV-1-uninfected RV144 vaccine recipients were reimmunized 6–8 years later with AIDSVAX B/E gp120 alone, ALVAC-HIV alone, or a combination of ALVAC-HIV and AIDSVAX B/E gp120 inmore »« less
Cited by 30
https://doi.org/10.1371/journal.ppat.1006182

Full Text Available
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Journal Article Rademeyer, Cecilia ; Korber, Bette ; Seaman, Michael S. ; ... - PLoS Pathogens

The development of biomedical interventions to reduce acquisition of HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high HIV-1 envelope diversity. Two large prophylactic trials in high incidence, clade C epidemic regions in southern Africa are imminent; passive administration of the monoclonal antibody VRC01, and active immunization with a clade C modified RV144-like vaccines. We have created a large representative panel of C clade viruses to enable assessment of antibody responses to vaccines and natural infection in Southern Africa, and we investigated the genotypic and neutralization properties of recently transmitted clade C viruses tomore »« less
https://doi.org/10.1371/journal.ppat.1005742

Full Text Available
Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques

Journal Article Santra, Sampa ; Tomaras, Georgia D. ; Warrier, Ranjit ; ... - PLoS Pathogens

HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4⁺ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1 antibodies that are most likely protective, they are not induced with current vaccine candidates. In contrast, antibodies that do not neutralize primary HIV-1 strains in the TZM-bl infection assay are readily induced by current vaccine candidates and have also been implicated as secondary correlates of decreased HIV-1 risk in the RV144 vaccine efficacy trial. Here, we have studied the capacity of anti-Env monoclonal antibodies (mAbs) against either the immunodominant regionmore »« less
Cited by 112
https://doi.org/10.1371/journal.ppat.1005042

Full Text Available

Similar Records